According to a report, “Pharmacogenomics Technology/Theranostics/Companion Diagnostics (CDx) Market Analysis By Therapeutic Area (Oncology Neurological, Cardiovascular, Immunology Disorders), By Technology, And Segment Forecasts, 2018 – 2025”, published by Grand View Research, Inc., The global pharmacogenomics technology (theranostics and companion diagnostics) market is expected to reach USD 18.3 billion by 2025. Diagnostics is coming to grips with the wave of pharmacogenomic tests that are followed by new biological therapy introductions. These tests enable cost-effective treatment and also add value to the process of drug-development. Advantages associated with the usage of these tests such as disease risk prediction, patient stratification, and therapeutic response monitoring over the traditional methods is anticipated to significant source of progress in this market. pharmacogenomics testing products aid physicians in individualizing and optimization of patient’s therapeutic regimen.
Key Takeaways from the report:
-
Oncology is estimated to account for the largest revenue share owing to the presence of substantial number of products in this segment
-
Furthermore, precision oncology investigators envision in giving multiple medications, in varied sorts of combinations, in an effort to squelch a tumor rather than just temper its growth
-
Aforementioned fact is responsible for the estimated revenue share of cancer in pharmacogenomics technology market
-
Polymerase Chain Reaction (PCR) was the largest revenue grossing segment of the with respect to technology for theranostics
-
Advantages associated with the use of the PCR technique makes it current workhorse of clinical diagnostics
-
Moreover, reproducible and precise results produced with the assays without sacrificing the sensitivity are responsible for the estimated share
-
North American region dominates the market as a consequence of economic incentives for drug developers to pair their products with diagnostics.
-
Asia Pacific market is projected to showcase fastest growth over the forecast period as the companies are engaged in capturing untapped opportunities
-
Key players operating include F Hoffman La Roche, Agilent Technologies, Thermo Fisher Scientific Inc., GE Healthcare, Pfizer, Qiagen NV, Leica Biosystems Nussloch GmBH, and Foundation Medicine.
-
Diagnostic companies are positioning themselves to offer theranostic tools by widening the application of in-vitrodiagnostic technologies to include more than just disease detection
Germany pharmacogenomics technology market by therapeutic area, 2014 – 2025 (USD Million)
Browse More Reports in Clinical Diagnostics Industry:
Point of Care Molecular Diagnostics Market: Ongoing research & development to miniaturize molecular diagnostics testing that provides enhanced near patient testing with high accuracy & lesser turnaround times are major factors expected to reinforce the high growth potential for POC MDx products.
In-Vitro Colorectal Cancer Screening Tests Market: Increasing incidences of colorectal cancer and the development of novel CRC screening tests employing methods of genetic screening are some primary factors expected to drive market growth over the forecast period.
Pharmacogenomics technology (theranostics & CDx) market, by region, 2016 (%)
However, presence of challenges pertaining to early integration of pharmacogenomic based testing into drug development time lines for gaining the approval simultaneously is anticipated to impede growth. Proper designing and implementation of clinical trials in order to identify individual as well as population variations from a given therapy has become a necessary attribute for the success of theranostics.
Grand View Research has segmented the pharmacogenomics technology (theranostics and companion diagnostics) market on the basis of therapeutic area, technology, and region:
Therapeutic Area Outlook (Revenue, USD Million; 2014 – 2025)
-
Oncology
-
Lung Cancer
-
Breast Cancer
-
Colorectal Cancer
-
Cervical Cancer
-
Others
-
-
Neurological Disorders
-
Cardiovascular Disease
-
Immunological Disorders
-
Others
Technology Outlook (Revenue, USD Million; 2014 – 2025)
-
PCR
-
In-situ Hybridization
-
Immunohistochemistry
-
Sequencing
-
Others
Regional Outlook (Revenue, USD Million; 2014 – 2025)
-
North America
-
U.S.
-
Canada
-
-
Europe
-
Germany
-
UK
-
-
Asia Pacific
-
China
-
Japan
-
-
Latin America
-
Brazil
-
-
Middle East & Africa
-
South Africa
Explore the BI enabled intuitive market research database, Navigate with Grand View Compass, by Grand View Research, Inc.
About Grand View Research
Grand View Research provides syndicated as well as customized research reports and consulting services on 46 industries across 25 major countries worldwide. This U.S.-based market research and consulting company is registered in California and headquartered in San Francisco. Comprising over 425 analysts and consultants, the company adds 1200+ market research reports to its extensive database each year. Supported by an interactive market intelligence platform, the team at Grand View Research guides Fortune 500 companies and prominent academic institutes in comprehending the global and regional business environment and carefully identifying future opportunities.
For more information: www.grandviewresearch.com
Media Contact
Company Name: Grand View Research, Inc.
Contact Person: Sherry James, Corporate Sales Specialist – U.S.A.
Email: Send Email
Phone: 1-415-349-0058, Toll Free: 1-888-202-9519
Address:201, Spear Street, 1100
City: San Francisco
State: California
Country: Switzerland
Website: www.grandviewresearch.com/industry-analysis/pharmacogenomics-technology-theranostics-companion-diagnostics-cdx-market